Repligen Corporation (RGEN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
↓
54.72
↓-32% vs avg
5yr avg: 81.04
30Y Low3.2·High91.2
P/FCF
↓
79.30
↓-54% vs avg
5yr avg: 171.86
30Y Low4.0·High135.3
P/B Ratio
↓
3.55
↓-35% vs avg
5yr avg: 5.48
30Y Low1.5·High8.7
ROE
↓
2.4%
↑-43% vs avg
5yr avg: 4.2%
30Y Low-153%·High56%
Debt/EBITDA
↑
4.99
↓-7% vs avg
5yr avg: 5.39
30Y Low1.5·High13.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RGEN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Repligen Corporation trades at 153.5x earnings, 5% below its 5-year average of 161.6x, sitting at the 79th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 594%. On a free-cash-flow basis, the stock trades at 79.3x P/FCF, 54% below the 5-year average of 171.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.4B | $9.3B | $8.1B | $10.1B | $9.7B | $15.2B | $10.3B | $4.6B | $2.4B | $1.4B | $1.1B |
| Enterprise Value | $7.6B | $9.4B | $8.0B | $10.1B | $9.6B | $14.9B | $9.9B | $4.3B | $2.3B | $1.3B | $1.0B |
| P/E Ratio → | 153.51 | 190.53 | — | 285.40 | 52.26 | 118.23 | 172.64 | 210.23 | 142.54 | 50.39 | 90.65 |
| P/S Ratio | 10.09 | 12.55 | 12.69 | 16.03 | 12.14 | 22.62 | 28.20 | 16.84 | 12.36 | 10.06 | 10.05 |
| P/B Ratio | 3.55 | 4.40 | 4.08 | 5.16 | 5.09 | 8.67 | 6.75 | 4.29 | 3.90 | 2.40 | 6.23 |
| P/FCF | 79.30 | 98.70 | 56.51 | 135.28 | 251.12 | 317.67 | 284.65 | 103.30 | 128.02 | 118.39 | 328.83 |
| P/OCF | 63.41 | 78.93 | 45.91 | 88.98 | 56.53 | 127.43 | 164.91 | 67.72 | 73.18 | 81.39 | 139.73 |
P/E links to full P/E history page with 30-year chart
RGEN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Repligen Corporation's enterprise value stands at 54.7x EBITDA, 32% below its 5-year average of 81.0x. The Healthcare sector median is 14.2x, placing the stock at a 285% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.72 | 12.58 | 15.97 | 12.01 | 22.26 | 26.99 | 15.86 | 11.89 | 9.53 | 9.61 |
| EV / EBITDA | 54.72 | 67.90 | 155.12 | 75.45 | 34.18 | 72.57 | 91.23 | 70.33 | 55.26 | 55.03 | 47.14 |
| EV / EBIT | 127.06 | 109.78 | — | 170.53 | 43.70 | 90.57 | 138.55 | 120.94 | 88.80 | 98.32 | 52.27 |
| EV / FCF | — | 100.02 | 56.01 | 134.75 | 248.53 | 312.69 | 272.47 | 97.28 | 123.19 | 112.18 | 314.28 |
RGEN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Repligen Corporation earns an operating margin of 8.1%. ROE of 2.4% is modest. ROIC of 2.2% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1% | 47.1% | 43.3% | 44.0% | 56.9% | 58.3% | 53.1% | 51.1% | 55.7% | 52.5% | 54.9% |
| Operating Margin | 8.1% | 8.1% | -5.5% | 7.5% | 28.0% | 24.9% | 22.2% | 14.8% | 13.4% | 9.9% | 15.3% |
| Net Profit Margin | 6.6% | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | 16.4% | 7.9% | 8.6% | 20.1% | 11.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.4% | 2.4% | -1.3% | 1.8% | 10.2% | 7.8% | 4.6% | 2.6% | 2.8% | 7.5% | 8.0% |
| ROA | 1.7% | 1.7% | -0.9% | 1.3% | 7.6% | 6.0% | 3.6% | 2.8% | 12.8% | 13.9% | 5.4% |
| ROIC | 2.2% | 2.2% | -1.4% | 1.9% | 10.1% | 9.7% | 6.5% | 4.6% | 3.7% | 3.3% | 14.0% |
| ROCE | 2.2% | 2.2% | -1.3% | 2.0% | 10.9% | 9.4% | 5.5% | 5.9% | 49.6% | 7.7% | 8.1% |
RGEN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Repligen Corporation carries a Debt/EBITDA ratio of 5.0x, which is highly leveraged (55% above the sector average of 3.2x). Net debt stands at $124M ($690M total debt minus $566M cash). Interest coverage of 3.7x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.33 | 0.33 | 0.35 | 0.36 | 0.22 | 0.21 | 0.18 | 0.25 | 0.17 | 0.17 | 0.56 |
| Debt / EBITDA | 4.99 | 4.99 | 13.34 | 5.32 | 1.50 | 1.78 | 2.54 | 4.32 | 2.48 | 4.06 | 4.47 |
| Net Debt / Equity | — | 0.06 | -0.04 | -0.02 | -0.05 | -0.14 | -0.29 | -0.25 | -0.15 | -0.13 | -0.28 |
| Net Debt / EBITDA | 0.90 | 0.90 | -1.38 | -0.30 | -0.36 | -1.16 | -4.08 | -4.35 | -2.16 | -3.05 | -2.18 |
| Debt / FCF | — | 1.32 | -0.50 | -0.53 | -2.59 | -4.98 | -12.18 | -6.02 | -4.82 | -6.21 | -14.55 |
| Interest Coverage | 3.69 | 3.69 | -0.28 | 5.91 | 74.00 | 12.96 | 5.88 | 3.81 | 3.87 | 2.13 | 5.10 |
RGEN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Repligen Corporation's current ratio of 8.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 7.12x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 6.74x to 8.37x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.37 | 8.37 | 8.41 | 6.74 | 2.47 | 2.48 | 2.83 | 13.28 | 2.12 | 9.63 | 8.74 |
| Quick Ratio | 7.12 | 7.12 | 7.28 | 5.51 | 1.88 | 1.99 | 2.53 | 12.15 | 1.80 | 8.08 | 7.57 |
| Cash Ratio | 5.65 | 5.65 | 5.97 | 4.56 | 1.54 | 1.61 | 2.25 | 10.94 | 1.49 | 6.89 | 6.73 |
| Asset Turnover | — | 0.25 | 0.22 | 0.22 | 0.32 | 0.28 | 0.19 | 0.19 | 1.39 | 1.17 | 0.36 |
| Inventory Turnover | 2.29 | 2.29 | 2.52 | 1.75 | 1.45 | 1.51 | 1.81 | 2.41 | 2.03 | 1.72 | 1.91 |
| Days Sales Outstanding | — | 78.41 | 77.16 | 71.67 | 52.94 | 63.92 | 71.14 | 58.98 | 67.26 | 71.68 | 55.98 |
RGEN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Repligen Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.7% | 0.5% | — | 0.4% | 1.9% | 0.8% | 0.6% | 0.5% | 0.7% | 2.0% | 1.1% |
| FCF Yield | 1.3% | 1.0% | 1.8% | 0.7% | 0.4% | 0.3% | 0.4% | 1.0% | 0.8% | 0.8% | 0.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $56M | $56M | $57M | $57M | $54M | $49M | $45M | $39M | $34M |
Peer Comparison
Compare RGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RGENYou | $7B | 153.5 | 54.7 | 79.3 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 FTRE | $1B | -1.4 | 28.3 | 16.4 | 15.6% | -1.1% | -102.4% | -1.6% | 1.4 |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 AZTA | $1B | -19.1 | 18.1 | 28.0 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 BRKR | $9B | -381.5 | 22.9 | 201.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 CRL | $9B | -63.6 | 12.9 | 17.2 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 ICLR | $11B | 50.3 | 10.1 | 13.0 | 26.4% | 12.3% | 2.5% | 6.2% | 2.5 |
 RVTY | $11B | 48.1 | 20.9 | 22.0 | 53.1% | 12.5% | 3.2% | 2.7% | 5.3 |
 TECH | $9B | 126.0 | 44.1 | 35.4 | 64.8% | 8.4% | 3.7% | 3.4% | 2.1 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
RGEN — Frequently Asked Questions
Quick answers to the most common questions about buying RGEN stock.
What is Repligen Corporation's P/E ratio?
Repligen Corporation's current P/E ratio is 153.5x. The historical average is 88.0x. This places it at the 79th percentile of its historical range.
What is Repligen Corporation's EV/EBITDA?
Repligen Corporation's current EV/EBITDA is 54.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.6x.
What is Repligen Corporation's ROE?
Repligen Corporation's return on equity (ROE) is 2.4%. The historical average is -4.8%.
Is RGEN stock overvalued?
Based on historical data, Repligen Corporation is trading at a P/E of 153.5x. This is at the 79th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Repligen Corporation's profit margins?
Repligen Corporation has 47.1% gross margin and 8.1% operating margin.
How much debt does Repligen Corporation have?
Repligen Corporation's Debt/EBITDA ratio is 5.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.